"Isomorphic Labs' Lucrative Drug Discovery Deals with Novartis and Lilly"

Isomorphic Labs, a drug discovery spin-out of DeepMind, has partnered with Eli Lilly and Novartis to use AI for drug discovery, with deals totaling $3 billion. Isomorphic will receive upfront payments and potential milestone-based incentives. The company utilizes DeepMind's AlphaFold 2 AI technology to predict protein structures, aiding in drug design. While not perfect, AlphaFold has shown promise in designing potential drugs for diseases like liver cancer and is being applied to neglected diseases. Isomorphic is under pressure to turn a profit after recording a loss in 2021.